me-troe-NI-da-zole
REMS
Spectrum:
Absorption: 80% absorbed after oral administration. Minimal absorption after topical or vaginal application.
Distribution: Widely distributed into most tissues and fluids, including CSF.
Half-Life: Neonates: 25–75 hr; Children and adults: 6–12 hr.
(PO, IV = plasma concentrations; topical = improvement in rosacea)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| PO | rapid | 1–3 hr | 8 hr |
| PO-ER | rapid | unknown | up to 24 hr |
| IV | rapid | end of infusion | 6–8 hr |
| Topical | 3 wk | 9 wk | 12 hr |
| Vaginal | unknown | 6–12 hr | 12 hr |
Contraindicated in:
Use Cautiously in:
Derm: ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS (AGEP), DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), rash, STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS (TEN), urticaria, topical onlyburning, mild dryness, skin irritation, transient redness
EENT: hearing impairment, optic neuropathy, tearing (topical only)
GI: abdominal pain, anorexia, nausea, diarrhea, dry mouth, furry tongue, glossitis, unpleasant taste, vomiting
Hemat: leukopenia
Local: phlebitis at IV site
Neuro: dizziness, headache, aseptic meningitis (IV), encephalopathy (IV), peripheral neuropathy, psychosis, SEIZURES
Misc: superinfection
Drug-drug:
Lab Test Considerations:
IV Administration:
NDC Code